A peritoneal atomization drug delivery device and a sterile protective operating sleeve

Abstract

The present invention discloses an abdominal atomization drug delivery instrument and a sterile protective operating sleeve, which relate to the technical field of medical devices, and include a high-voltage generating unit, a power unit, a transmission unit, a negative pressure unit, a temperature and pressure unit, and a central control module; wherein the power unit drives the piston of the high-voltage generating unit through the transmission unit to generate ultra-high pressure on the drug liquid, so that the drug liquid is transported to the atomization end through a high-pressure-resistant pipeline, atomized into extremely fine particles and targetedly sprayed to the abdominal lesion site; the temperature and pressure unit adopts PWM control and SPI sensing technology to achieve precise thermal and pressure control of the drug liquid and abdominal cavity gas; the negative pressure unit synchronously inhales the aerosol, and discharges it harmlessly after high-efficiency filtration; the central control module dynamically optimizes the atomization particle size and the temperature and pressure of the drug liquid and the abdominal cavity through multi-parameter closed-loop regulation, so that the drug penetration depth and heating treatment produce a synergistic effect, thereby improving the permeability and penetration depth of the drug liquid particles, improving the efficacy, shortening the treatment time, and reducing side effects.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to a peritoneal atomization drug delivery device and a sterile protective operating cover. Background Art

[0002] The treatment of abdominal diseases has been continuously developing in recent years. Intraperitoneal local drug delivery technology is an important means of treating diseases such as abdominal tumors, postoperative infections and peritoneal metastasis. Among them, drug atomization penetration therapy has become one of the important means of treatment with intraperitoneal local drug delivery technology.

[0003] Traditional drug delivery methods mostly rely on intravenous injection or intraperitoneal perfusion, but there are problems such as uneven drug distribution, insufficient local concentration, limited penetration effect, low treatment efficiency and obvious systemic side effects. In recent years, with the development of minimally invasive medicine, atomization drug delivery technology has gradually attracted attention due to its advantages of achieving targeted drug delivery and increasing local drug concentration. Some atomization devices in the existing technology have been tried for abdominal treatment, such as placing an atomizing nozzle into the abdominal cavity through a laparoscopic channel and using air pressure to drive the atomization spray of the drug solution. However, this type of technology still has significant limitations in practical applications.

[0004] How to improve the coverage and permeability of drugs in the lesion site during the treatment process to improve the treatment effect has become an important direction of current medical research and technological development.

[0005] Currently, most peritoneal atomization devices used abroad are based on conventional air pressure atomization principles (such as the Venturi effect or ultrasonic atomization). Their atomization pressures are typically below 2-2.5 MPa, and the resulting drug particles are typically distributed in the 50-200 μm diameter range. However, research has shown that drug particles must be smaller than 10 μm to effectively penetrate the peritoneal mesothelial cell layer, and the atomized particle size of existing devices is insufficient to meet therapeutic penetration requirements.

[0006] Furthermore, the atomization field formed by traditional atomizing nozzles in a low-pressure environment has limited coverage, which can easily lead to incomplete drug coverage of the lesion area. Some existing technologies attempt to improve atomization uniformity by modifying the nozzle structure (such as multi-hole dispersed nozzles), but problems such as agglomeration of atomized particles and rapid sedimentation of drug solution particles still exist in the complex internal structure of the abdominal cavity.

[0007] In particular, the existing technology lacks the coordinated design of heated drug delivery and high-pressure atomization, making it difficult to maximize the utilization of the thermodynamic effects of drugs.

[0008] In terms of equipment reliability, existing devices generally face the technical bottleneck of insufficient high-pressure sealing. When the atomization pressure exceeds 5MPa, conventional atomization chambers are prone to liquid leakage, and the nozzle structure is prone to deformation or clogging by liquid particles under long-term high-pressure operation.

[0009] Although the abdominal cavity atomization device disclosed in the prior art uses titanium alloy material for its atomizing nozzle to improve pressure resistance, its atomization efficiency and particle size control have not yet broken through the technical bottleneck.

[0010] Therefore, the defects of the existing technology are: insufficient control of atomization particle size, the diameter of the drug solution particles produced by conventional atomization devices is relatively large (>50μm), and it is difficult to penetrate the peritoneal tissue to reach an effective therapeutic concentration; poor targeting coverage capability, the existing nozzle design cannot form a uniform atomization field in the complex abdominal cavity, resulting in uneven distribution of drugs in the lesion area; lack of thermal synergy, lack of a coordinated structural design of the heating drug delivery system and high-pressure atomization, and failure to fully exert the synergistic effect of thermal therapy to enhance drug penetration; high-pressure stability defects, the atomization system has the risk of sealing failure or nozzle clogging under high-pressure conditions, which restricts the atomization efficiency and equipment reliability.

[0011] In summary, it is found that the existing technology has at least the following technical problems:

[0012] Existing drug liquid atomization devices used for intraperitoneal drug administration have technical problems such as large atomization particle size, low atomization uniformity, lack of thermal synergy and low high-pressure stability, which makes it difficult to meet the penetration requirements of intraperitoneal treatment. Summary of the Invention

[0013] The purpose of the present invention is to provide an intraperitoneal atomization drug delivery instrument and a sterile protective operating cover to solve the technical problems of existing liquid drug atomization devices used for intraperitoneal drug delivery treatment, such as large atomization particle size, low atomization uniformity, lack of thermal synergy and low high-pressure stability.

[0014] The various technical effects that can be produced by the preferred technical solution among the various technical solutions provided by the present invention are described in detail below.

[0015] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0016] The present invention provides an abdominal atomization drug delivery instrument, comprising a high-voltage generating unit, the atomization end of the high-voltage generating unit extending into the abdominal cavity to be treated, for atomizing the loaded drug solution and spraying it on the affected area; a power unit and a transmission unit, the power unit driving the transmission unit by rotation, the transmission unit converting the rotation into movement, and pushing the piston in the high-voltage generating unit to apply ultra-high pressure to the drug solution, so that the drug solution reaches the atomization end by power, and after the atomization end atomizes the drug solution, the drug solution is sprayed out in the form of extremely fine mist particles; a negative pressure unit, the negative pressure end of the negative pressure unit extending into the abdominal cavity, sucking out the generated abdominal aerosol, and filtering it for harmless treatment; and a temperature and pressure unit, the temperature and pressure unit The temperature and pressure unit is provided with a plurality of heating devices and sensors, and controls the heating devices through PWM to heat the medicine liquid and the abdominal gas, and interprets the sensors through SPI to obtain the medicine liquid temperature, abdominal gas temperature and abdominal gas pressure; and a central control module, which receives the operator's setting data as an operating indicator, and electrically controls the power unit, the transmission unit, the negative pressure unit and the temperature and pressure unit to cooperate with each other, perform information exchange to form a closed-loop control, and complete the coordinated action control of the medicine liquid atomization degree, medicine liquid temperature, medicine liquid injection volume, abdominal gas temperature, abdominal gas pressure and exhaust purification, thereby realizing high-pressure atomization heating drug delivery treatment in the abdominal cavity.

[0017] In one embodiment, the high-voltage generating unit includes an explosion-proof syringe, a liquid pipe and an atomizing nozzle, and the liquid pipe is a high-pressure resistant pipe; the explosion-proof syringe is loaded with a liquid medicine for drug administration, and the two ends of the liquid pipe are respectively connected to the liquid outlet end of the explosion-proof syringe and the liquid inlet end of the atomizing nozzle; the atomizing end is provided on the atomizing nozzle; the piston is provided in the explosion-proof syringe, one end of the piston is in contact with the liquid medicine, and the other end is connected to the movable end of the transmission unit.

[0018] In one embodiment, the particle size of the mist liquid sprayed by the atomizing nozzle is less than or equal to 10 μm, and the ultra-high pressure is 5-9 MPa.

[0019] In one embodiment, the barrel of the explosion-proof syringe is a thickened disposable barrel.

[0020] In one embodiment, the barrel of the explosion-proof syringe is made of a high-pressure-resistant and corrosion-resistant material.

[0021] In one embodiment, the explosion-proof syringe includes a barrel, an explosion-proof shell and the piston; the explosion-proof shell is sleeved on the outside of the barrel, one end of the explosion-proof shell is sealedly connected to the outer wall of the liquid outlet end of the barrel, and is provided with a hole for the liquid outlet end to extend out; the other end of the explosion-proof shell is provided with an openable and closable sealing component; the sealing component is used to replace the barrel when opened, and is used to allow the movable end of the transmission unit to pass through and seal the outer wall of the movable end when closed.

[0022] In one embodiment, the transmission unit includes a transmission screw and a transmission nut, and the output end of the power unit is transmission-connected to the transmission screw or the transmission nut, and the power unit transmits the output rotation to the transmission screw or the transmission nut, and the transmission screw or the transmission nut converts the rotation into displacement and transmits it to the piston.

[0023] In one embodiment, when the transmission screw receives the rotation of the power unit, the transmission nut moves in a straight line along the axis of the transmission screw, and the transmission nut transmits the displacement to the piston; the transmission unit is also provided with a guide rod, which is slidingly connected to the transmission nut; a push rod is also provided between the transmission nut and the piston, and the push rod connects the transmission nut and the piston, and the piston and the push rod are detachable.

[0024] In one of the embodiments, when the transmission nut receives the rotation of the power unit, the transmission screw moves in a straight line along the axis of the transmission nut, and the transmission screw transmits the displacement to the piston; the transmission unit is provided with a rotating base, and the transmission nut is rotatably mounted on the rotating base, and the power unit is rotatably connected to the transmission nut to drive the transmission nut to rotate; the transmission screw passes through the center screw hole of the transmission nut, and the transmission nut drives the transmission screw to move.

[0025] In one embodiment, the power unit includes a servo motor and a servo driver, the output end of the servo motor is connected to the input end of the transmission unit, and the transmission unit receives the rotation of the servo motor; the servo driver is electrically connected to the servo motor, and the servo driver is electrically connected to the central control module, receiving data from the central control module to control the start displacement, stop displacement, and displacement distance and speed of the piston.

[0026] In one embodiment, the negative pressure unit includes a suction component, a filter component and a suction tube; the suction tube is used to extend into the abdominal cavity and suck out the abdominal aerosol with the negative pressure suction force generated by the suction component, and the sucked abdominal aerosol is filtered and purified by the filter component and then discharged.

[0027] In one embodiment, the suction component is connected to the air outlet end of the filter component through a pipeline, and the suction tube is connected to the air inlet end of the filter component; the filter component is filled with a purified liquid, and the peritoneal aerosol sucked by the suction tube is passed into the purified liquid. After the purified liquid absorbs the pollutants in the peritoneal aerosol, the purified gas is released. The purified gas enters the suction component through the air outlet end of the filter component and is discharged through the suction component.

[0028] In one embodiment, the suction tube is connected to the negative pressure end of the suction component, and the exhaust end of the suction component is connected to the filter component through a pipe. The suction component passes the sucked abdominal aerosol into the air inlet end of the filter component; the filter component is filled with a purification liquid, and the abdominal aerosol passes into the purification liquid. After the purification liquid absorbs the pollutants in the abdominal aerosol, purified gas is released, and the purified gas is discharged through the air outlet end of the filter component.

[0029] In one embodiment, a liquid quality sensor is provided in the purified liquid of the filter component, and the liquid quality sensor is electrically connected to the central control module to monitor the contamination degree of the purified liquid and output the contamination data of the purified liquid to the central control module. The central control module determines the contamination degree or cleanliness of the purified liquid through a built-in algorithm.

[0030] In one embodiment, a gas quality sensor is provided inside or outside the gas outlet end of the filter component on the path of the discharged purified gas, for monitoring the contamination level of the purified gas and outputting the contamination data of the purified gas to the central control module. The central control module determines the contamination level or cleanliness of the purified gas through a built-in algorithm.

[0031] In one embodiment, the temperature pressure unit includes a liquid medicine heater, a first temperature sensor and a second temperature sensor electrically connected to the central control module; the liquid medicine heater is arranged on the high-voltage generating unit, and heats the liquid medicine loaded in the high-voltage generating unit to reach the preset temperature of the central control module; the first temperature sensor is used to monitor the real-time temperature of the liquid medicine, and the second temperature sensor is used to monitor the output temperature of the liquid medicine heater, and transmit the real-time temperature of the liquid medicine and the output temperature data of the liquid medicine heater to the central control module, and the central control module performs closed-loop control of the real-time temperature of the liquid medicine and the liquid medicine heater; and an abdominal cavity heater, a third temperature sensor and a fourth temperature sensor electrically connected to the central control module; the abdominal cavity heater is arranged on the abdomen, and is used to heat the abdomen and conduct heat to the abdomen The abdominal gas in the cavity is heated to the preset temperature of the central control module; the third temperature sensor is used to monitor the real-time temperature of the abdominal gas, and the fourth temperature sensor is used to monitor the output temperature of the abdominal heater, and transmit the real-time temperature of the abdominal gas and the output temperature data of the abdominal heater to the central control module, and the central control module performs closed-loop control on the real-time temperature of the abdominal gas and the abdominal heater; and an abdominal pressure sensor electrically connected to the central control module, the abdominal pressure sensor is used to monitor the abdominal pressure, and transmit the abdominal pressure data to the central control module, and the central control module jointly controls the pressure and flow of the atomized liquid sprayed by the high-pressure generating unit, and controls the pressure and flow of the abdominal aerosol sucked out by the negative pressure unit, and coordinates the control of the abdominal pressure in a closed-loop manner.

[0032] In one embodiment, the high-voltage generating unit is equipped with a limit module, a position detection module and a liquid medicine pressure module which are electrically connected to the central control module and perform data exchange; the limit module is used to obtain the starting position and the final position of the piston, and feed back the starting position and the final position data of the piston to the central control module; the position detection module is used to obtain the current position of the piston, feed back the current position data of the piston to the central control module, and calculate the current liquid medicine injection volume through the built-in algorithm of the central control module; the liquid medicine pressure module is used to detect the current pressure of the liquid medicine in the high-voltage generating unit, and feed back the current pressure data of the liquid medicine to the central control module.

[0033] In one embodiment, a rotation sensor is installed on the power unit for detecting the number of rotations and the rotation speed output by the power unit, and feeding back the number of rotations and the rotation speed data output by the power unit to the central control module.

[0034] In one embodiment, the central control module coordinates the power unit, the transmission unit and the high-voltage generating unit in a closed-loop control manner by obtaining the starting position, final position and current position of the piston, obtaining the current pressure data of the medicine liquid in the high-voltage generating unit, and obtaining the number of rotations and rotation speed data output by the power unit to control the atomization degree and injection volume of the medicine liquid.

[0035] The present invention also provides a sterile protective operating sleeve, comprising a sterile operating sleeve and the above-mentioned abdominal atomization drug delivery device. The sterile operating sleeve is arranged on the abdominal wound to isolate the abdominal wound from the external environment. A sterile environment is formed inside the sterile operating sleeve, allowing the atomization end to be extended into the abdominal cavity to be treated in a sterile manner to perform high-pressure atomization heating drug delivery treatment.

[0036] The present invention also provides a PC-side processor, including a PC processing unit and the above-mentioned intraperitoneal nebulizer drug delivery device, wherein the PC processing unit is electrically connected to the central control module and performs data interaction, and is used to receive the drug delivery data set by the user and convert it into interactive data and transmit it to the central control module.

[0037] The present invention also provides an interactor, including an operation screen and the above-mentioned PC processor, wherein the operation screen is electrically connected to the PC processing unit and performs data interaction, and is used for the user to set medication instructions, and convert them into interactive instructions and transmit them to the PC processing unit.

[0038] Beneficial effects of the present invention:

[0039] The present invention provides an abdominal atomization drug delivery instrument and a sterile protective operating sleeve. The abdominal atomization drug delivery instrument comprises a high-voltage generating unit, the atomization end of the high-voltage generating unit extends into the abdominal cavity to be treated, and is used to spray the loaded drug solution on the affected area after atomization; a power unit and a transmission unit, the power unit drives the transmission unit by rotation, the transmission unit converts the rotation into movement, and pushes the piston in the high-voltage generating unit to apply ultra-high pressure to the drug solution, the drug solution reaches the atomization end by power, and after the atomization end atomizes the drug solution, the drug solution is sprayed out in the form of extremely fine mist liquid particles; and a negative pressure unit, the negative pressure end of the negative pressure unit extends into the abdominal cavity, sucks out the generated abdominal aerosol, and filters it for harmless treatment; and a temperature pressure A power unit, the temperature and pressure unit is provided with multiple heating devices and sensors, and the heating devices are controlled by PWM to heat the liquid medicine and the abdominal gas, and the sensors are interpreted by SPI to obtain the liquid medicine temperature, the abdominal gas temperature and the abdominal gas pressure; and a central control module, the central control module receives the operator's setting data as an operating indicator, and electrically connects and controls the power unit, the transmission unit, the negative pressure unit and the temperature and pressure unit to cooperate with each other, perform information exchange to form a closed-loop control, and complete the coordinated action control of the liquid medicine atomization degree, liquid medicine temperature, liquid medicine injection volume, abdominal gas temperature, abdominal gas pressure and exhaust purification, thereby realizing high-pressure atomization heating drug administration treatment in the abdominal cavity. A sterile protective operation cover provided in an embodiment of the present invention includes a sterile operation cover and the above-mentioned abdominal atomization drug administration instrument, the sterile operation cover is provided on the abdominal wound, used to isolate the abdominal wound from the external environment, and form a sterile environment in the sterile operation cover for the atomization end to be extended into the abdominal cavity to be treated in a sterile manner to perform high-pressure atomization heating drug administration treatment.

[0040] In response to the core problems of existing intraperitoneal atomization drug delivery devices, such as large atomized particle size, poor targeting, lack of thermal synergy and insufficient high-pressure stability, the above-mentioned technical solution uses ultra-high pressure atomization technology, heated drug delivery coordinated control and intelligent closed-loop system design to atomize the drug solution into extremely fine particles. Through atomization spraying, the drug solution is evenly distributed in the lesion site in the abdominal cavity, thereby improving the drug penetration effect, thereby enhancing the accuracy and efficacy of treatment and reducing side effects.

[0041] Specifically, its significant technical advantages and clinical application value are as follows:

[0042] (1) Breaking through the bottleneck of drug penetration through ultra-high pressure atomization technology

[0043] Under the action of the high-pressure generating unit that pressurizes the drug liquid to an ultra-high pressure of 5-9MPa, the drug liquid required for treatment is atomized into sufficiently small drug liquid particles through the atomization end; using the principle of particle penetration, the drug liquid atomized into sufficiently small particles is delivered to the lesion site, allowing the drug liquid to fully contact the abdominal lesion site, thereby achieving the effect of improving the efficacy and reducing the side effects of treatment. Compared with traditional chemotherapy, it reduces 90% of the drug side effects, can achieve the advantages of fast effect, small side effects, and greatly shortened treatment time.

[0044] Through the precise coordination of the power unit and the transmission unit, combined with the high-pressure resistant atomizing nozzle that can be arranged at the atomizing end, the diameter of the atomized liquid medicine particles can be precisely controlled within an extremely fine range of 5-10 μm.

[0045] Experimental data show that the atomized drug liquid particles with a diameter range of 5-10μm can enable the drug liquid to penetrate the peritoneal mesothelial cell layer, enhance the drug penetration depth and permeability, and significantly increase the effective drug concentration at the lesion site.

[0046] At the same time, the real-time pressure feedback from the temperature and pressure unit to the central control module ensures that the atomization process of the liquid medicine is stable and reliable, avoiding the agglomeration of liquid medicine particles or the blockage of the atomizing nozzle at the atomizing end due to sudden pressure changes.

[0047] (2) Enhanced therapeutic targeting through thermal synergy

[0048] The closed-loop control algorithm integrating the temperature and pressure unit and the central control module realizes the synergistic effect of heating the drug solution and heating the abdominal cavity gas; in the heated drug delivery environment, the diffusion coefficient of the atomized drug solution particles is increased by 1.8-2.3 times, and at the same time, the high temperature induces an increase in the permeability of the tumor cell membrane, which helps the drug to reach the lesion directly, thereby increasing the effect of the drug, improving the targeting of drug treatment, and realizing precise drug delivery and precise treatment.

[0049] The SPI bus collects the pressure and temperature data of the abdominal gas collected by the sensor in real time to ensure that the environment for heated atomization of drugs meets the optimal thermodynamic window, and controls the temperature of the atomized drug particles reaching the abdominal cavity and the temperature of the abdominal gas within an error of ±0.5°C to avoid the risk of thermal damage.

[0050] (3) Improving the reliability of intraperitoneal atomizers through intelligent closed-loop control

[0051] The central control module achieves dynamic regulation through multimodal signal fusion: Adaptive compensation of liquid medicine pressure: when the atomization resistance of the atomization end suddenly changes, the power unit cooperates with the transmission unit to automatically adjust the injection speed of the liquid medicine to maintain a constant atomization pressure of the liquid medicine;

[0052] Thermal balance mechanism: The central control module dynamically adjusts the heating power of the heating device for heating the medical solution and the heating device for heating the abdominal gas based on the temperature data feedback of the abdominal gas to avoid local overheating of the abdominal gas;

[0053] Purification linkage of abdominal aerosol: The spraying of liquid medicine particles at the atomization end of the negative pressure unit and the high-pressure generating unit is started, stopped and regulated synchronously to ensure that the residual amount of abdominal aerosol is controlled within 0.1μg / m³, greatly reducing the risk of abdominal infection and drug side effects.

[0054] (4) Enhance the therapeutic advantages of intraperitoneal atomizers through multi-dimensional collaboration

[0055] The power unit, the transmission unit, the high-voltage generating unit, the negative pressure unit and the temperature-pressure unit cooperate to achieve triple synergistic effects of ultra-high-pressure atomization, heated atomization drug administration and closed-loop control of temperature and pressure. When performing intraperitoneal atomization drug administration, the drug efficacy can be improved, and the tumor inhibition rate can be improved, the side effects can be significantly reduced, and the treatment cycle can be shortened.

[0056] (5) The intraperitoneal nebulizer has high drug compatibility and scalability

[0057] Modular design: The atomizing end can be adapted to atomizing nozzles of different apertures, and can spray liquid medicine particles of different sizes according to different treatment plans, meeting the diverse needs of intraperitoneal heated high-pressure atomization administration from chemotherapy drugs to biological agents.

[0058] Data interconnection: The central control module collects the treatment parameters of intraperitoneal atomization drug administration, retains the treatment data for subsequent treatment, and even stores it in the cloud. It conducts AI-assisted analysis of the drug administration dynamics, drug administration pharmacology, and drug administration effect of the treatment plan, and provides data support for the subsequent formulation of personalized intraperitoneal atomization drug administration treatment plans based on different conditions, so as to provide better treatment plans, maximize the effect of the treatment drugs, and alleviate patients' pain.

[0059] In summary, the present invention realizes ultra-high pressure atomization particle size control through the power unit, the transmission unit and the high-pressure generating unit, realizes thermal synergy to enhance drug penetration through the temperature and pressure unit and the negative pressure unit, and the central control module collects sensor data and performs intelligent closed-loop regulation and multi-unit integrated structure, so as to achieve the reduction of the particle size of the atomized particles of the drug solution, spray the atomized particles of the drug solution on the lesion site in the abdominal cavity and distribute them evenly, thereby improving the drug penetration depth and permeability, thereby improving the accuracy and efficacy of intraperitoneal atomization drug administration treatment, reducing the side effects of intraperitoneal drug administration, and solving the technical problems of existing drug atomization devices for intraperitoneal drug administration treatment, such as large atomization particle size, low atomization uniformity, lack of thermal synergy and low high-pressure stability, and providing an efficient, accurate and safe intraperitoneal high-pressure atomization drug administration technical solution for local treatment of abdominal tumors and peritoneal diseases; and the technical indicators of the intraperitoneal atomization drug delivery instrument of the present invention have reached the international leading level and have significant clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the technical solution of the present invention, the following is a brief introduction to the drawings required for use in the implementation. Obviously, the drawings described below are only some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0061] Figure 1 This is one of the control principle diagrams of the abdominal atomization drug delivery device of the present invention;

[0062] Figure 2 This is the second schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0063] Figure 3 This is the third schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0064] Figure 4 This is the fourth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0065] Figure 5 This is the fifth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0066] Figure 6 This is the sixth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0067] Figure 7 This is the seventh schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0068] Figure 8 This is the eighth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0069] Figure 9 This is the ninth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0070] Figure 10 This is the tenth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention;

[0071] Figure 11 This is a schematic diagram of the control principle of the peritoneal atomization drug delivery device and the PC-side processor of the present invention;

[0072] Figure 12 It is a schematic diagram of the control principle of the interactor and PC-side processor of the present invention. DETAILED DESCRIPTION

[0073] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention will be further described below with reference to the accompanying drawings and examples. However, the example embodiments can be implemented in various forms and should not be understood as being limited to the embodiments described herein; on the contrary, these embodiments are provided to make the present invention more comprehensive and complete, and to fully convey the concepts of the example embodiments to those skilled in the art. The same figure marks in the figures represent the same or similar structures, and their repeated descriptions will be omitted. The words expressing position and direction described in the present invention are all explained with reference to the accompanying drawings as examples, but changes can be made as needed, and the changes made are all included in the scope of protection of the present invention. The drawings of the present invention are only used to illustrate the relative position relationship and do not represent the true proportion.

[0074] Treatment options for abdominal diseases have continued to evolve in recent years. Intraperitoneal drug delivery is an important approach for treating conditions such as abdominal tumors, postoperative infections, and peritoneal metastases. Among these, drug aerosol infiltration therapy has become a key approach. Traditional drug delivery methods often rely on intravenous injection or intraperitoneal perfusion, but these methods are associated with issues such as uneven drug distribution, insufficient local concentration, limited penetration, low therapeutic efficiency, and significant systemic side effects. In recent years, with the advancement of minimally invasive medicine, aerosol drug delivery technology has gained increasing attention due to its advantages in enabling targeted drug delivery and increasing local drug concentration. Several existing aerosol devices have been tried for use in abdominal treatments. For example, aerosol nozzles are placed into the abdominal cavity through a laparoscopic channel, using pneumatic drive to atomize and spray the drug solution. However, these technologies still have significant limitations in practical application. Improving drug coverage and penetration within the lesion during treatment to enhance therapeutic efficacy has become a key area of current medical research and technological development.

[0075] Currently, most peritoneal atomization devices available internationally are based on conventional pneumatic atomization principles, with atomization pressures typically below 2-2.5 MPa. The resulting drug particles typically range in diameter from 50 to 200 μm. However, studies have shown that drug particles must be below 10 μm to effectively penetrate the peritoneal mesothelial cell layer, and the atomized particle size of existing devices is insufficient to meet therapeutic penetration requirements. Furthermore, the atomization field generated by traditional atomizer nozzles under low pressure has limited coverage, which can lead to incomplete drug coverage of the lesion. Some existing technologies attempt to improve atomization uniformity by modifying the nozzle structure (such as multi-hole dispersed nozzles), but problems persist in the complex internal structure of the peritoneal cavity, such as agglomeration of atomized particles and rapid deposition of drug particles. In particular, existing technologies lack a coordinated design for heated drug delivery and high-pressure atomization, making it difficult to maximize the thermodynamic effects of drugs. Regarding device reliability, existing devices generally face the technical bottleneck of insufficient high-pressure sealing. When the atomization pressure exceeds 5MPa, conventional atomization chambers are prone to drug leakage, and the nozzles are prone to structural deformation or clogging by drug particles under prolonged high-pressure operation. While existing abdominal atomization devices utilize titanium alloys for their atomization nozzles to improve pressure resistance, their atomization efficiency and particle size control remain technically limited.

[0076] Therefore, the defects of the existing technology are: insufficient control of atomization particle size, the diameter of the drug solution particles produced by conventional atomization devices is relatively large, and it is difficult to penetrate the peritoneal tissue to reach an effective therapeutic concentration; poor targeting coverage capability, the existing nozzle design cannot form a uniform atomization field in the complex abdominal cavity, resulting in uneven distribution of drugs in the lesion area; lack of thermal synergy, lack of a coordinated structural design of the heating drug delivery system and high-pressure atomization, and failure to fully exert the synergistic effect of thermal therapy to enhance drug penetration; high-pressure stability defects, the atomization system has the risk of sealing failure or nozzle clogging under high-pressure conditions, which restricts the atomization efficiency and equipment reliability.

[0077] In view of this, a specific embodiment of the present invention provides an intraperitoneal nebulizer drug delivery instrument and a sterile protective operating sleeve, wherein the intraperitoneal nebulizer drug delivery instrument includes a high-voltage generating unit, a power unit, a transmission unit, a negative pressure unit, a temperature and pressure unit and a central control module; wherein the power unit drives the piston of the high-voltage generating unit through the transmission unit to generate an ultra-high pressure of 5-9 MPa on the drug solution, so that the drug solution is transported to the atomization end through a high-pressure resistant pipeline, atomized into extremely fine particles of 5-10 μm and targetedly sprayed to the abdominal lesion site; the temperature and pressure unit adopts PWM control and SPI sensing technology to achieve precise thermal and pressure control of the drug solution and the abdominal cavity gas; the negative pressure unit The aerosol is inhaled synchronously and discharged harmlessly after high-efficiency filtration; the central control module reduces pressure and temperature fluctuations through multi-parameter closed-loop regulation, dynamically optimizes the atomized particle size and the temperature and pressure of the drug solution and the abdominal cavity, so that the drug penetration depth and heating treatment produce a synergistic effect, improve the permeability and penetration depth of the drug solution particles, improve the efficacy, shorten the treatment time, and reduce the side effects on the human body by 90% compared with traditional large-dose intravenous drug injection therapy. It also improves the targeting of drug penetration; it effectively solves the technical problems of existing drug solution atomization devices used for intraperitoneal drug administration, such as large atomized particle size, low atomization uniformity, lack of thermal synergy and low high-pressure stability.

[0078] The technical solutions in the embodiments of the present invention will be described clearly and completely below with reference to the accompanying drawings in the embodiments of the present invention.

[0079] Figure 1 This is one of the control principle diagrams of the abdominal atomization drug delivery device of the present invention; Figure 2 This is the second schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0080] The first embodiment of the intraperitoneal atomization drug delivery device is as follows Figure 1As shown, it includes a high-pressure generating unit, the atomizing end of the high-pressure generating unit extends into the abdominal cavity to be treated, and is used to spray the loaded medicine liquid on the affected area after atomization; as well as a power unit and a transmission unit, the power unit drives the transmission unit by rotation, the transmission unit converts the rotation into movement, and pushes the piston in the high-pressure generating unit to apply ultra-high pressure to the medicine liquid, so that the medicine liquid reaches the atomizing end with power, and after the atomizing end atomizes the medicine liquid, the medicine liquid is sprayed out in the form of extremely fine mist particles; as well as a negative pressure unit, the negative pressure end of the negative pressure unit extends into the abdominal cavity, sucks out the generated abdominal aerosol, and filters it for harmless treatment; and a temperature and pressure unit, the temperature and pressure unit is provided with multiple A heating device and a sensor are provided, and the heating device is controlled by PWM to heat the medicine liquid and the abdominal gas, and the sensor is interpreted by SPI to obtain the medicine liquid temperature, abdominal gas temperature and abdominal gas pressure; and a central control module is provided, which receives the operator's setting data as an operating indicator, and electrically connects and controls the power unit, transmission unit, negative pressure unit and temperature and pressure unit to cooperate with each other, exchange information to form a closed-loop control, and complete the coordinated action control of the medicine liquid atomization degree, medicine liquid temperature, medicine liquid injection volume, abdominal gas temperature, abdominal gas pressure and exhaust purification, thereby realizing high-pressure atomization heating drug delivery treatment in the abdominal cavity.

[0081] Among them, this embodiment is as follows Figure 2 As shown, the temperature and pressure unit is provided with a plurality of heating devices including a liquid medicine heater and an abdominal cavity heater; the sensors include a first temperature sensor, a second temperature sensor, a third temperature sensor, a fourth temperature sensor and an abdominal cavity pressure sensor.

[0082] Regarding the specific structure of the above-mentioned high-voltage generating unit, the high-voltage generating unit includes an explosion-proof syringe, a liquid pipe and an atomizing nozzle, and the liquid pipe is a high-pressure resistant pipe; the explosion-proof syringe is loaded with a liquid medicine for drug treatment, and the two ends of the liquid pipe are respectively connected to the liquid outlet end of the explosion-proof syringe and the liquid inlet end of the atomizing nozzle; the atomizing end is provided on the atomizing nozzle; the piston is provided in the explosion-proof syringe, one end of the piston is in contact with the liquid medicine, and the other end is connected to the moving end of the transmission unit.

[0083] During use, the two ends of the liquid pipe are respectively connected to the liquid outlet of the explosion-proof syringe and the liquid inlet of the atomizing nozzle, so as to transmit the pressurized liquid in the explosion-proof syringe to the atomizing nozzle.

[0084] Specifically, the particle size of the mist liquid sprayed by the atomizing nozzle is less than or equal to 10 μm, thereby atomizing the liquid medicine into extremely fine liquid medicine particles for discharge, improving the penetration effect of the medicine in the affected area in the abdominal cavity, and thus improving the efficacy of the medicine.

[0085] In response to the core problems of existing intraperitoneal atomization drug delivery devices, such as large atomized particle size, poor targeting, lack of thermal synergy and insufficient high-pressure stability, the above technical solutions use ultra-high pressure atomization technology, heated drug delivery coordinated control and intelligent closed-loop system design to atomize the drug solution into extremely fine particles. Through atomization spraying, the drug solution is evenly distributed in the lesion site in the abdominal cavity, thereby improving the drug penetration effect, thereby enhancing the accuracy and efficacy of treatment and reducing side effects.

[0086] The significant technical advantages and clinical application value it achieves are as follows:

[0087] (1) Breaking through the bottleneck of drug penetration through ultra-high pressure atomization technology

[0088] Under the action of ultra-high pressure, the drug liquid required for treatment is atomized into sufficiently small drug liquid particles through the atomization end; using the principle of particle penetration, the drug liquid atomized into sufficiently small particles is delivered to the lesion site, allowing the drug liquid to fully contact the abdominal lesion site, thereby achieving the effect of improving the efficacy and reducing the side effects of treatment. Compared with traditional chemotherapy, it reduces 90% of the drug side effects, can achieve the advantages of fast effect, small side effects, and greatly shortened treatment time.

[0089] Through the precise coordination of the power unit and the transmission unit, combined with the high-pressure resistant atomizing nozzle that can be set at the atomizing end, the diameter of the atomized liquid particles can be accurately controlled within an extremely fine range of 5-10μm.

[0090] Among them, through the precise coordination of the power unit and the transmission unit, the pressurized pressure of the medicine liquid in the high-pressure generating unit can reach the ultra-high pressure range of 5-9MPa. Combined with the high-pressure resistant atomizing nozzle set at the atomizing end, the compressive strength of the high-pressure resistant atomizing nozzle reaches ≥30MPa; thereby, the diameter of the atomized medicine liquid particles is precisely controlled within an extremely fine range of 5-10μm, and the atomized particle size of the medicine liquid is reduced by more than 80% compared with the atomized particle diameter of the medicine liquid of the existing hot perfusion treatment atomization technology.

[0091] Experimental data shows that the power unit, transmission unit, and high-voltage generating unit work together to achieve a stable ultra-high pressure of 8.0MP±0.5 for the pressurized drug solution within the high-voltage generating unit. This ultra-high pressure atomizes the drug solution into drug particles with a diameter of 5-10μm, allowing the drug solution to penetrate the peritoneal mesothelial cell layer, increasing the drug penetration depth and permeability, and significantly improving the effective drug concentration at the lesion site.

[0092] Among them, when performing intraperitoneal atomization administration, using drug liquid particles with a diameter of 5-10μm can increase the penetration depth of the drug liquid through the peritoneal mesothelial cell layer by 3-5 times, and make the local drug concentration at the site where the drug liquid is sprayed by heating administration reach 20-50 times that of intravenous injection, significantly increasing the effective drug concentration at the lesion site, thereby improving the targeting of drug administration, achieving fixed-point administration, reducing incidental side effects, and also improving efficacy and reducing the burden of drug metabolism on organs.

[0093] At the same time, the real-time pressure feedback from the temperature and pressure unit to the central control module ensures the stability and reliability of the liquid atomization process, avoiding the agglomeration of liquid particles or the blockage of the atomizing nozzle at the atomization end due to sudden pressure changes;

[0094] Among them, the temperature and pressure unit provides real-time pressure feedback to the central control module, so that the pressure fluctuation of the liquid medicine can be controlled within ±0.5MPa.

[0095] (2) Enhanced therapeutic targeting through thermal synergy

[0096] The closed-loop control algorithm of the integrated temperature and pressure unit and the central control module realizes the synergistic effect of drug solution heating and abdominal cavity gas heating; in the heated drug delivery environment, the diffusion coefficient of the atomized drug solution particles increases by 1.8-2.3 times. At the same time, high temperature induces an increase in the permeability of tumor cell membranes, which helps the drug to reach the lesion directly, increases the drug effect, improves the targeting of drug treatment, and realizes precise drug delivery and precise treatment.

[0097] Among them, the closed-loop control algorithms applied by the central control module include PWM control or PID+PWM regulation; the temperature range of drug solution heating is controlled at 35-45°C, and the temperature range of peritoneal gas heating is controlled at 38-43°C; through the coordination of drug solution heating and peritoneal gas heating, a heated drug delivery environment is formed. In the heated drug delivery environment, the diffusion coefficient of the atomized drug solution particles is increased by 1.8-2.3 times. At the same time, high temperature induces an increase in the permeability of tumor cell membranes. At 42°C, the cell membrane permeability is greatly improved.

[0098] The SPI bus collects the pressure and temperature data of the abdominal gas collected by the sensor in real time to ensure that the environment for heated atomization of drugs meets the optimal thermodynamic window, and controls the temperature of the atomized drug particles reaching the abdominal cavity and the temperature of the abdominal gas within an error of ±0.5°C to avoid the risk of thermal damage.

[0099] (3) Improving the reliability of intraperitoneal atomizers through intelligent closed-loop control

[0100] The central control module achieves dynamic regulation through multimodal signal fusion: Adaptive compensation of drug liquid pressure: When the atomizer sprays drug liquid into the abdominal cavity and encounters tissue adhesion, resulting in a sudden change in atomization resistance, the power unit cooperates with the transmission unit to automatically adjust the injection speed of the drug liquid to maintain a constant drug liquid atomization pressure;

[0101] The central control module integrates multimodal signals, including drug solution pressure, peritoneal gas pressure, drug solution temperature, peritoneal gas temperature, and atomized drug injection flow rate, collected by subordinate sensors. To maintain constant atomized drug pressure, the power unit and transmission unit automatically adjust the injection speed, with a controlled response time of less than 50ms. This increases the sensitivity of the injection adjustment, maintaining a constant atomized drug pressure during atomization and particle injection.

[0102] Thermal balance mechanism: The central control module dynamically adjusts the heating power of the heating devices for heating the medical solution and the heating devices for heating the abdominal gas based on the temperature data feedback of the abdominal gas to avoid local overheating of the abdominal gas;

[0103] Among them, the heating power of the heating device for heating the medical solution and the heating device for heating the abdominal cavity gas can be adjusted with an accuracy of ±5W.

[0104] Purification linkage of abdominal aerosol: Synchronous start-stop and regulation of the drug liquid particle injection at the atomization end of the negative pressure unit and the high-pressure generating unit ensures that the residual amount of abdominal aerosol is controlled within 0.1μg / m³, significantly reducing the risk of abdominal infection and drug side effects;

[0105] Among them, the suction efficiency of the negative pressure unit in the abdominal cavity reaches ≥5L / min, so that when the abdominal cavity pressure suddenly increases due to changes in body position, the negative pressure unit can provide sufficient negative pressure suction, quickly adjust the intra-abdominal pressure, and realize real-time follow-up control of the intra-abdominal pressure, ensuring that the residual aerosol in the abdominal cavity is controlled within 0.1μg / m³, and the residual aerosol in the abdominal cavity is reduced by 90% compared with the traditional heated perfusion technology.

[0106] (4) Enhance the therapeutic advantages of intraperitoneal atomizers through multi-dimensional collaboration

[0107] The power unit, transmission unit, high-voltage generating unit, negative pressure unit, and temperature-pressure unit work together to achieve triple synergy: ultra-high-pressure atomization, heated atomization drug delivery, and closed-loop control of temperature and pressure. This improves drug efficacy during intraperitoneal atomization drug delivery, resulting in increased tumor inhibition rates, significantly reduced side effects, and shortened treatment cycles.

[0108] The triple synergistic effects include achieving ultra-high penetration of the drug solution into the lesion site in the abdominal cavity through ultra-high pressure atomization, enhancing the thermal sensitization of the abdominal cavity and improving the drug absorption capacity by heating the drug solution and atomizing it, and achieving precise drug delivery through closed-loop control of the drug solution temperature and pressure.

[0109] After improving the drug efficacy, the systemic blood drug concentration index of the drug solution entering the body is only 1 / 15 of that of intravenous injection, thereby reducing the liver and kidney toxicity indicators. However, due to the high drug targeting, although the drug dosage is not large, the drug's efficacy is improved and the side effects are significantly reduced; the treatment cycle is shortened, and the single treatment time is ≤30 minutes, which is greatly shortened compared to the 2-3 hours required for traditional hot perfusion, and the equipment durability is >500 high-pressure cycles.

[0110] (5) The intraperitoneal nebulizer has high drug compatibility and scalability

[0111] Modular design: The atomizer can be adapted to atomizer nozzles of different apertures, allowing it to spray liquid particles of different sizes according to different treatment plans, meeting the diverse needs of intraperitoneal heated high-pressure atomization drug delivery, from chemotherapy drugs to biological agents;

[0112] Among them, the atomizing end can adapt to atomizing nozzles with different apertures, so that the atomized particle size can be adjusted to 5-10 microns, 10-20μm, 20-50μm and 50-200μm; under different treatment plans, the atomizing end can spray liquid particles of different particle sizes to meet the diversified drug delivery needs of various drugs, from chemotherapy drugs such as paclitaxel to biological agents such as PD-1 antibodies.

[0113] Data interconnection: The central control module collects treatment parameters for intraperitoneal atomization, retains treatment data for subsequent use, and even stores it in the cloud. This allows AI-assisted analysis of the treatment plan's drug delivery dynamics, pharmacology, and efficacy. This provides data support for the subsequent development of personalized intraperitoneal atomization treatment plans based on different conditions, enabling better treatment plans to maximize the effectiveness of the treatment drugs and alleviate patients' pain.

[0114] Among them, by analyzing the treatment data, the optimal atomization particle size and heating temperature can be recommended according to the tumor type, so as to provide a better treatment plan.

[0115] In summary, the present invention realizes ultra-high pressure atomization particle size control through the power unit, transmission unit and high-pressure generating unit, realizes thermal synergy to enhance drug penetration through the temperature and pressure unit and the negative pressure unit, and the central control module collects sensor data and performs intelligent closed-loop regulation and multi-unit integrated structure, so as to achieve the reduction of the particle size of the atomized particles of the drug solution, and the atomized particles of the drug solution are evenly distributed in the lesion site in the abdominal cavity, thereby improving the drug penetration depth and permeability, thereby improving the accuracy and efficacy of intraperitoneal atomization drug administration treatment, reducing the side effects of intraperitoneal drug administration, and solving the technical problems of the existing drug solution atomization device for intraperitoneal drug administration treatment, such as large atomization particle size, low atomization uniformity, lack of thermal synergy and low high-pressure stability, and providing an efficient, accurate and safe intraperitoneal high-pressure atomization drug administration technical solution for the local treatment of abdominal tumors and peritoneal diseases; and the technical indicators of the intraperitoneal atomization drug delivery instrument of the present invention, such as atomization particle size, pressure stability and thermal control accuracy, have reached the international leading level and have significant clinical application value.

[0116] As an optional implementation method,

[0117] Regarding the specific structure of the above-mentioned explosion-proof syringe, the barrel of the explosion-proof syringe is a thickened disposable barrel.

[0118] Specifically, attention is paid to the material of the barrel of the explosion-proof syringe. The barrel of the explosion-proof syringe is made of a high-pressure-resistant and corrosion-resistant material.

[0119] During application, the cylinder is made of high-pressure resistant and corrosion-resistant materials including medical-grade stainless steel, medical-grade plastics, medical-grade ceramics, medical-grade composite materials and other high-performance materials.

[0120] Due to the particularity of intraperitoneal high-pressure atomization drug delivery, the drug composition is relatively complex and its stability is sensitive, and it even has a certain amount of radioactivity. Therefore, the explosion-proof syringe used to load the drug solution must be disposable and have the characteristics of high pressure resistance and corrosion resistance. It is also necessary to avoid the problem of metal releasing impurities under high pressure and highly corrosive drug solution, and consider the disposable cost of the explosion-proof syringe.

[0121] Therefore, it is more reasonable to use medical grade plastic as the material for explosion-proof syringes.

[0122] One of the implementations of the transmission unit may be a screw-nut transmission structure.

[0123] Specifically, the transmission unit includes a transmission screw and a transmission nut. The output end of the power unit is connected to the transmission screw or the transmission nut. The power unit transmits the output rotation to the transmission screw or the transmission nut, and the transmission screw or the transmission nut converts the rotation into displacement and transmits it to the piston.

[0124] During application, the screw-nut transmission structure has the function of converting the rotational motion of the power unit into displacement motion, and the screw has high repeatability and small axial clearance, which is suitable for cooperating with the power unit to accurately control the displacement of the piston of the high-pressure generating unit, thereby accurately controlling the injection volume. The liquid medicine needs to use ultra-high pressure to achieve extremely fine atomization of the liquid medicine particles, and the screw-nut transmission structure has a self-locking function, which can withstand large axial forces. The power unit combined with the reducer can easily convert the torque amplification into a huge axial pressure applied to the piston, making it suitable as a transmission unit structure for high-pressure atomization drug delivery.

[0125] Figure 3 This is the third schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0126] Regarding the specific structure of the power unit, this embodiment Figure 3 As shown, the power unit is a servo power source, and the power unit consists of a servo motor and a servo driver. The output end of the servo motor is connected to the input end of the transmission unit, and the transmission unit receives the rotation of the servo motor; the servo driver is electrically connected to the servo motor, and the servo driver is electrically connected to the central control module, which receives data from the central control module to control the start displacement, stop displacement, and displacement distance and speed of the piston.

[0127] During application, the servo driver receives the command signal from the central control module, and the servo driver controls the rotation of the servo motor. The servo motor transmits the rotational motion to the transmission unit, driving the piston in the high-pressure generating unit to move, generating a linear pressure of 5-9MPa on the liquid medicine. The servo driver adjusts the servo motor torque and speed in real time based on the built-in PID algorithm to ensure that the atomization pressure fluctuation range is ≤±0.5MPa, avoiding excessive fluctuations in the particle size of the atomized liquid medicine particles caused by sudden changes in resistance. The sensor monitors the pressure of the piston in real time and feeds back the pressure data to the central control module, thereby dynamically correcting the servo motor speed to achieve stable atomization output of the liquid medicine at the atomization end under ultra-high pressure atomization.

[0128] The powertrain consists of a servo-controlled power unit and a transmission unit. This structure overcomes the pressure hysteresis problem of traditional pneumatic and hydraulic drive systems and can still maintain the uniformity of the atomized particle size of the liquid medicine at the atomization end under ultra-high pressure conditions.

[0129] Figure 4 This is the fourth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0130] In addition, in order to increase the closed-loop control of the power unit, this embodiment Figure 4 As shown, a rotation sensor is installed on the power unit.

[0131] Furthermore, the rotation sensor is electrically connected to the servo driver of the power unit.

[0132] During application, the rotation sensor is used to detect the number of rotations and the rotation speed output by the power unit, and feeds back the number of rotations and the rotation speed data output by the power unit to the central control module.

[0133] Specifically, the rotation sensor is a rotary encoder when the power unit is a servo motor power component. The rotary encoder is installed on the shaft of the servo motor. When the shaft of the servo motor rotates, the code disk of the rotary encoder is driven to rotate together. By detecting the rotation of the code disk, the motion state, number of motion circles, motion angle and other data of the servo motor shaft are identified.

[0134] The rotation sensor is electrically connected to the servo driver, which feeds back the measured servo motor data to the servo driver, and controls the rotation of the servo motor through the servo driver to form a closed-loop control. The servo driver also receives control information from the central control module, thereby forming data exchange with the power unit and forming an intelligent closed-loop control of output and feedback.

[0135] One of the embodiments of the above-mentioned transmission unit and power unit may be that the power unit may be a magnetic drive mechanism, and the transmission unit may be a push rod and a guide rod, one end of the push rod is connected to the piston, and the other end is connected to the output end of the magnetic drive mechanism, and the guide rod is connected to the push rod through a slider. Under the guidance of the guide rod, the push rod is pushed by the output end of the magnetic drive mechanism to power the piston, pressurize the liquid medicine, and make the liquid medicine have sufficient atomization in the atomizing nozzle.

[0136] In order to prevent the magnetic drive mechanism from suddenly losing power, which may cause the decompression of the drug solution and the sudden decompression and suction of the gas or liquid in the abdominal cavity, resulting in the risk of decompression of intraperitoneal atomization drug delivery, a self-locking mechanism is provided on the output end or push rod of the magnetic drive mechanism to prevent the output end or push rod of the magnetic drive mechanism from producing a backward stroke after losing power.

[0137] Specifically, the self-locking mechanism may be one of a ratchet mechanism, a worm gear mechanism, and a worm gear mechanism.

[0138] Figure 5 This is the fifth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0139] Regarding the specific structure of the negative pressure unit, this embodiment Figure 5 As shown, the negative pressure unit includes a suction component, a filter component and a suction tube;

[0140] Specifically, the suction component is electrically connected to the central control module; the suction tube is used to extend into the abdominal cavity, and suck out the abdominal aerosol with the negative pressure suction force generated by the suction component, and the sucked abdominal aerosol is filtered and purified by the filter component and then discharged.

[0141] During use, the suction component draws the abdominal aerosol according to the negative pressure value set by the central control module. Through the algorithm of the central control module, the power unit, transmission unit and high-voltage generating unit are coordinated to dynamically match the suction efficiency with the atomization injection rate; through the dynamically adjusted suction and injection coordination mechanism, efficient aerosol purification in the abdominal cavity is achieved.

[0142] The system is regulated by the central control module and executed by the power unit, transmission unit, high-voltage generating unit and negative pressure unit to realize closed-loop control of the entire process of atomization-suction-purification. In a single treatment, 99.9% of residual aerosols can be removed to avoid systemic toxicity caused by drug diffusion. At the same time, the gas pressure balance in the abdominal cavity is maintained to prevent pneumoperitoneum complications.

[0143] Among them, in order to ensure that the aerosol in the abdominal cavity can be sucked out clean, an aerosol sensor for monitoring the aerosol content in the abdominal cavity is installed on the suction tube inserted into the abdominal cavity, so that the central control module can receive data from the aerosol sensor, thereby monitoring the abdominal aerosol content in the abdominal cavity, calculating the current residual aerosol in the abdominal cavity, and verifying whether the aerosol in the abdominal cavity is sucked out cleanly. By detecting the aerosol content in the abdominal cavity and coordinating with the suction components, it is ensured that the aerosol in the abdominal cavity is sucked out cleanly.

[0144] Regarding the specific structure of the temperature and pressure unit and the connection method between each component and the temperature and pressure unit, the temperature and pressure unit includes a liquid medicine heater electrically connected to the central control module, a first temperature sensor, and a second temperature sensor; the liquid medicine heater is provided on the high-voltage generating unit and heats the liquid medicine loaded in the high-voltage generating unit to a preset temperature of the central control module; the detection end of the first temperature sensor is provided on or in the high-voltage generating unit and is used to measure the real-time temperature of the liquid medicine by contacting or non-contacting the liquid medicine; the detection end of the second temperature sensor is provided on the liquid medicine heater;

[0145] and an abdominal cavity heater, a third temperature sensor, and a fourth temperature sensor electrically connected to the central control module; the abdominal cavity heater is arranged on the abdomen; the detection end of the third temperature sensor extends into the abdominal cavity to detect the temperature of the abdominal cavity gas, and the detection end of the fourth temperature sensor is arranged on the abdominal cavity heater;

[0146] and an abdominal pressure sensor electrically connected to the central control module, wherein the detection end of the abdominal pressure sensor extends into the abdominal cavity to detect the pressure of the abdominal cavity gas.

[0147] During application, the first temperature sensor is used to monitor the real-time temperature of the liquid medicine; the second temperature sensor is used to monitor the output temperature of the liquid medicine heater, and transmit the real-time temperature of the liquid medicine and the output temperature data of the liquid medicine heater to the central control module, which performs closed-loop control on the real-time temperature of the liquid medicine and the liquid medicine heater;

[0148] The central control module implements closed-loop control logic for the real-time temperature of the liquid medicine and the liquid medicine heater. Liquid medicine heating is initiated through the liquid medicine heater. The first temperature sensor monitors the real-time temperature of the liquid medicine and feeds back the liquid medicine temperature information to the main control IC of the central control module. For example, heating is stopped when the temperature is above 43 degrees Celsius, and heating is resumed when the temperature is below 40 degrees Celsius.

[0149] The main control IC uses the PID feedback algorithm combined with the real-time temperature of the liquid medicine fed back by the first temperature sensor to control the carbon fiber heating wire in the liquid medicine heater to heat the liquid medicine; the second temperature sensor sends the collected real-time heating output temperature of the carbon fiber heating wire back to the main control IC, and controls the heating frequency and heating value of the carbon fiber heating wire through PWM to maintain its heating temperature at a constant temperature state with a temperature error of 0.5 degrees Celsius, thereby closed-loop controlling the temperature of the heated liquid medicine to keep the liquid temperature between 40 and 43 degrees Celsius.

[0150] The abdominal cavity heater is used to heat the abdomen and transfer the heat to the abdominal cavity gas in the abdominal cavity, so that the abdominal cavity gas is heated to the preset temperature of the central control module;

[0151] The third temperature sensor is used to monitor the real-time temperature of the abdominal cavity gas, and the fourth temperature sensor is used to monitor the output temperature of the abdominal cavity heater, and transmit the real-time temperature of the abdominal cavity gas and the output temperature data of the abdominal cavity heater to the central control module, and the central control module performs closed-loop control on the real-time temperature of the abdominal cavity gas and the abdominal cavity heater;

[0152] The central control module implements closed-loop control logic for the real-time temperature of the abdominal gas and the abdominal heater. The abdominal heater activates heating of the abdominal gas. The third temperature sensor monitors the real-time temperature of the abdominal gas and feeds back the abdominal gas temperature information to the main control IC of the central control module. For example, heating is stopped when the temperature is above 43 degrees Celsius, and heating is started when the temperature is below 38 degrees Celsius.

[0153] The main control IC uses the PID feedback algorithm combined with the real-time temperature of the abdominal gas fed back by the third temperature sensor to control the carbon fiber heating wire in the abdominal heater to heat the abdominal gas; the fourth temperature sensor transmits the collected real-time heating output temperature of the carbon fiber heating wire back to the main control IC, and controls the heating frequency and heating value of the carbon fiber heating wire through PWM to maintain its heating temperature at a constant temperature state with a temperature error of 0.5 degrees Celsius, thereby closed-loop controlling the temperature of the heated abdominal gas and keeping the abdominal gas temperature between 38 and 43 degrees Celsius.

[0154] The abdominal pressure sensor is used to monitor the abdominal pressure and transmit the abdominal pressure data to the central control module. The central control module, in conjunction with the power unit, controls the pressure and flow of the atomized liquid sprayed by the high-pressure generating unit and the pressure and flow of the abdominal aerosol sucked out by the negative pressure unit. The abdominal pressure is collaboratively controlled in a closed-loop control manner to maintain the stability of the abdominal pressure.

[0155] In order to achieve the abdominal cavity air pressure to the abdominal cavity environment required for atomization treatment, an air blower is provided for blowing air. The air blower is electrically connected to the central control module and is provided with an air blower tube for extending into the abdominal cavity.

[0156] The central control module cooperates with the power unit, high-voltage generating unit and negative pressure unit to control the control logic of the abdominal pressure in a closed loop. The abdominal heater is used to heat the abdominal gas. The abdominal pressure sensor collects the current abdominal pressure value, converts it into an electrical signal and sends it back to the main control IC. The main control IC controls the blowing volume through the PID feedback algorithm, and monitors the abdominal pressure through the abdominal pressure sensor. When the pressure reaches 12 mmHg, the air blower stops pressurizing the abdominal cavity. At the same time, after the abdominal pressure reaches the set pressure value and the air blower stops, the abdominal heater, power unit, high-voltage generating unit and negative pressure unit are turned on for intra-abdominal circulation to maintain the temperature of the gas in the abdominal cavity. When the air pressure drops, the air blower is started to supplement the pressure, thereby forming a closed-loop control of the abdominal pressure to maintain the stability of the abdominal pressure.

[0157] In order to obtain specific information about the position of the piston on the high-pressure generating unit, the central control module can be assisted to better control the displacement of the piston, thereby accurately controlling the injection volume; in addition, in order to accurately control the pressure of atomized drug delivery, the pressure of the drug solution in the high-pressure generating unit under the squeeze of the piston must also be monitored.

[0158] Figure 8 This is the eighth schematic diagram of the control principle of the peritoneal atomization drug delivery device of the present invention.

[0159] Specifically, this embodiment Figure 8 As shown, the high-voltage generating unit is equipped with a limit module, a position detection module and a liquid medicine pressure module which are electrically connected to the central control module, and perform data exchange; the limit module is used to obtain the starting position and the final position of the piston, and feed back the starting position and the final position data of the piston to the central control module; the position detection module is used to obtain the current position of the piston, feed back the current position data of the piston to the central control module, and calculate the current liquid medicine injection volume through the built-in algorithm of the central control module; the liquid medicine pressure module is used to detect the current pressure of the liquid medicine in the high-voltage generating unit, and feed back the current pressure data of the liquid medicine to the central control module.

[0160] Among them, regarding the specific structure of the above-mentioned limit module, the limit module is provided with an upper limit sensor and a lower limit sensor. The upper limit sensor and the lower limit sensor can be respectively set at the starting position and the final position of the piston moving in the high-pressure generating unit, and are used to obtain data on the starting position and the final position of the piston.

[0161] During application, the central control module obtains the starting position, final position and current position of the piston, obtains the current pressure data of the medicine liquid in the high-pressure generating unit, obtains the number of rotations and rotation speed data output by the power unit, and coordinates the power unit, transmission unit and high-pressure generating unit in a closed-loop control manner to control the atomization degree and injection volume of the medicine liquid; thereby accurately controlling the injection volume and other internal high-pressure drug delivery execution parameters, so as to achieve the functions of precise quantitative drug delivery and controllable atomization pressure at the atomization end, thereby improving the reliability of the intraperitoneal atomization drug delivery device.

[0162] In another embodiment, the limit module and the position detection module can be combined into a visual sensor or a laser scanning position sensor to detect the starting position, final position and current position of the piston in real time; without arranging multiple position detection sensors at different points on the piston movement path.

[0163] The second embodiment of the intraperitoneal nebulizer drug delivery device differs from the first embodiment in that the explosion-proof syringe includes a barrel, an explosion-proof shell and a piston; the explosion-proof shell is sleeved outside the barrel, one end of the explosion-proof shell is sealed with the outer wall of the liquid outlet end of the barrel, and is provided with a hole for the liquid outlet end to extend; the other end of the explosion-proof shell is provided with an openable and closable sealing component; the sealing component is used to replace the barrel when opened, and is used to allow the movable end of the transmission unit to pass through and seal the outer wall of the movable end when closed.

[0164] When in use, a sealing component is provided on the explosion-proof shell, which has the function of preventing the liquid medicine from flowing out from both ends of the explosion-proof shell after the cylinder body is replaced and burst.

[0165] The third embodiment of the intraperitoneal nebulizer drug delivery device differs from the first embodiment in that, regarding the specific structural connection and power transmission of the transmission screw, the drive nut and the power unit, when the transmission screw receives the rotation of the power unit, the transmission nut moves in a straight line along the axis of the transmission screw, and the transmission nut transmits the displacement to the piston; the transmission unit is also provided with a guide rod, which is slidingly connected to the transmission nut; a push rod is also provided between the transmission nut and the piston, the push rod connects the transmission nut and the piston, and the piston and the push rod are detachable.

[0166] During application, a push rod is provided between the transmission nut and the piston to limit the rotational freedom of the transmission nut, so that the transmission nut can convert the rotation of the transmission screw into displacement by engaging with the thread of the transmission screw.

[0167] The fourth embodiment of the intraperitoneal nebulizer drug delivery device is different from the first embodiment in that when the transmission nut receives the rotation of the power unit, the transmission nut serves as the main driving member and the transmission screw serves as the driven member.

[0168] During application, the transmission screw moves in a straight line along the axis of the transmission nut, and the transmission screw transmits the displacement to the piston; the transmission unit is provided with a rotating base, and the transmission nut is rotatably installed on the rotating base. The power unit is rotatably connected to the transmission nut to drive the transmission nut to rotate; the transmission screw passes through the center screw hole of the transmission nut, and the transmission nut drives the transmission screw to move.

[0169] Figure 6 This is the sixth schematic diagram of the control principle of the peritoneal atomization drug delivery device of the present invention.

[0170] The fifth embodiment of the peritoneal atomization drug delivery device is as follows Figure 6 As shown, the difference between this embodiment and the first embodiment is that one connection sequence of the negative pressure unit component structure is: connecting the suction tube, the filter component and the suction component in sequence along the direction of extracting the abdominal aerosol.

[0171] Specifically, the suction component is connected to the air outlet end of the filter component through a pipeline, and the suction pipe is connected to the air inlet end of the filter component.

[0172] During use, the filter component is filled with purified liquid. The abdominal aerosol sucked in by the suction tube is passed into the purified liquid. After the purified liquid absorbs the pollutants in the abdominal aerosol, purified gas is released. The purified gas enters the suction component through the air outlet end of the filter component and is discharged through the suction component.

[0173] Figure 7 This is the seventh schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0174] The sixth embodiment of the abdominal atomization drug delivery device is as follows Figure 7 As shown, the difference between this embodiment and the first embodiment is that one connection sequence of the negative pressure unit component structure is: connecting the suction tube, the suction component and the filter component in sequence along the direction of extracting the abdominal aerosol.

[0175] In a specific connection method, the suction pipe is connected to the negative pressure end of the suction component, and the exhaust end of the suction component is connected to the filter component through a pipeline.

[0176] During use, the suction component passes the sucked-out peritoneal aerosol into the air inlet end of the filter component; the filter component is filled with a purified liquid, and the peritoneal aerosol passes into the purified liquid. After the purified liquid absorbs the pollutants in the peritoneal aerosol, the purified gas is released, and the purified gas is discharged through the air outlet end of the filter component.

[0177] Figure 9This is the ninth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0178] The seventh embodiment of the peritoneal atomization drug delivery device is as follows Figure 9 As shown, the difference between this embodiment and the first embodiment is that a liquid quality sensor is provided in the purified liquid of the filter component, and the liquid quality sensor is electrically connected to the central control module.

[0179] During application, the liquid quality sensor is used to monitor the contamination level of the purified liquid and output the contamination data of the purified liquid to the central control module. The central control module determines the contamination level or cleanliness of the purified liquid through a built-in algorithm.

[0180] Specifically, the central control module determines the contamination or cleanliness of the purified liquid in the filter component through an algorithm and displays it on a display, thereby reminding the operator to replace the purified liquid in the filter component in time.

[0181] Figure 10 This is the tenth schematic diagram of the control principle of the abdominal atomization drug delivery device of the present invention.

[0182] The eighth embodiment of the peritoneal atomization drug delivery device is as follows Figure 10 As shown, the difference between this embodiment and the first embodiment is that a gas quality sensor is provided inside or outside the gas outlet end of the filter component on the path of the discharged purified gas.

[0183] The inside of the air outlet end of the filter component refers to the inside of the position where the air outlet end is connected to the exhaust pipe, and the outside of the air outlet end of the filter component refers to the inside of the exhaust pipe connected to the air outlet end.

[0184] During application, the gas quality sensor is used to monitor the contamination level of the purified gas and output the contamination data of the purified gas to the central control module. The central control module determines the contamination level or cleanliness of the purified gas through a built-in algorithm.

[0185] Specifically, after the central control module determines the contamination or cleanliness of the discharged purified gas, it further determines the contamination or cleanliness of the purified liquid in the filter component through an algorithm and displays it on the display, thereby reminding the operator to replace the purified liquid in the filter component in time.

[0186] When the need to replace the purified liquid is detected and determined in the manner of the seventh or eighth embodiment, a waste liquid container can be provided under the filter component, connected to the inner cavity of the filter component carrying the purified liquid via a drain pipe, and a drain electric control valve is provided on the drain end between the drain pipe and the inner cavity of the filter component carrying the purified liquid, the drain electric control valve is electrically connected to the central control module, and the drain electric control valve is controlled to be opened or closed by the central control module, thereby controlling the drainage;

[0187] A solution tank is arranged above the filter component, and the solution tank carries spare purified liquid. The solution tank is connected to the inner cavity of the filter component that carries the purified liquid through an inlet pipe, and an inlet electric control valve is arranged on the liquid inlet path, such as the liquid outlet end of the solution tank, the inlet pipe or the liquid inlet end of the inner cavity of the filter component that carries the purified liquid. The inlet electric control valve is electrically connected to the central control module, and the central control module controls the opening or closing of the inlet electric control valve, so as to automatically replenish new purified liquid from the solution tank to the inner cavity of the filter component that carries the purified liquid after the waste liquid is discharged.

[0188] When, in Example 8, the pollution degree of the purified gas is monitored by the gas quality sensor, and the central control module determines that the pollution degree or cleanliness of the discharged purified gas does not meet the emission index or purification index, a three-way air valve and a gas reflux pipe can be set, and the three-way air valve is installed between the air outlet end of the filter component, the exhaust pipe and the gas reflux pipe, and the air outlet end, the exhaust pipe and the gas reflux pipe of the filter component are connected with the three-way air valve, and the other end of the gas reflux pipe is connected to the air inlet end of the filter component, and a one-way valve is installed between the gas reflux pipe and the air inlet end of the filter component, which only allows the reflux gas to flow back from the air outlet end of the filter component to the air inlet end; thereby, the purified gas that does not meet the emission index or purification index is refluxed to the air inlet end of the filter component, and further purified to meet the emission index or purification index.

[0189] Regarding the specific structure and control method of the three-way air valve, the three-way air valve is an electric air valve, which is electrically connected to the central control module. The three-way air valve is controlled by the central control module to connect the air outlet end of the filter component with the exhaust pipe, or the air outlet end of the filter component with the gas return pipe.

[0190] Based on the above embodiment of the peritoneal atomization drug delivery device, a sterile protective operating cover is provided, comprising a sterile operating cover and the above peritoneal atomization drug delivery device.

[0191] Specifically, the sterile operating sleeve is placed on the abdominal wound to isolate the abdominal wound from the external environment, forming a sterile environment inside the sterile operating sleeve for the atomization end to be extended into the abdominal cavity to be treated in a sterile manner to implement high-pressure atomization drug administration treatment.

[0192] During application, the use of a sterile operating sleeve for intraperitoneal high-pressure atomization can reduce the postoperative infection rate, and there is no need to interrupt the operation to replace the sealing component during a single treatment, which significantly improves the safety and efficiency of intraperitoneal high-pressure atomization treatment.

[0193] Figure 11 It is a schematic diagram of the control principle of the peritoneal atomization drug delivery device and the PC-side processor of the present invention.

[0194] Based on the above embodiment of the peritoneal atomization drug delivery device, a PC-side processor is provided, which is characterized in that: Figure 11As shown, it includes a PC processing unit and the above-mentioned intraperitoneal atomization drug delivery device.

[0195] Specifically, the PC processing unit is electrically connected to the central control module and performs data interaction, and is used to receive medication data set by the user, and convert it into interactive data and transmit it to the central control module.

[0196] Among them, the PC processing unit reads the data of the power unit; the central processing module exchanges data with the power unit.

[0197] During application, the PC processing unit is electrically connected to the central control module and data is exchanged. The operator can set the treatment parameters through the PC processor, thereby improving the efficiency of setting the treatment parameters of intraperitoneal high-pressure atomization drug delivery and improving the standardization of the treatment process, meeting the requirements of precision medicine and medical data compliance.

[0198] Figure 12 It is a schematic diagram of the control principle of the interactor and PC-side processor of the present invention.

[0199] Based on the above embodiment of the peritoneal atomization drug delivery device, an interactive device is provided, such as Figure 12 As shown, it includes an operation screen and the above-mentioned PC processor.

[0200] Specifically, the operation screen is electrically connected to the PC processing unit and performs data interaction, so as to allow the user to set medication instructions, and convert the instructions into interactive instructions and transmit them to the PC processing unit.

[0201] During application, data is exchanged with the PC processor through the interactive device's operating screen. Through this design, the operator's complex operating steps when using the intraperitoneal nebulizer are simplified to within 3 steps, the efficiency of setting treatment parameters is also improved, the error rate can be reduced, and the training cycle for the use of the intraperitoneal nebulizer is further shortened, significantly reducing the risk of medical errors.

[0202] The technical features of the above embodiments may be combined arbitrarily. To simplify the description, not all possible combinations of the technical features in the above embodiments are described.

Claims

1. A peritoneal atomization drug delivery device, characterized in that: It includes a high-voltage generating unit, the atomizing end of which extends into the abdominal cavity to be treated and is used to spray the loaded liquid medicine on the affected area after atomization; and a power unit and a transmission unit, wherein the power unit drives the transmission unit, and the transmission unit pushes the piston in the high-pressure generating unit to apply ultra-high pressure to the liquid medicine, so that the liquid medicine is sprayed out in the form of extremely fine mist particles; and a negative pressure unit, wherein the negative pressure end of the negative pressure unit extends into the abdominal cavity, sucks out the generated abdominal aerosol, and filters it for harmless treatment; and a temperature and pressure unit, wherein the temperature and pressure unit is provided with a plurality of heating devices and sensors, and the heating devices are controlled by PWM to heat the liquid medicine and the abdominal gas, and the sensors are interpreted by SPI to obtain the liquid medicine temperature, the abdominal gas temperature and the abdominal gas pressure; and a central control module, which receives the operator's setting data as an operating indicator, and electrically controls the power unit, the transmission unit, the negative pressure unit, and the temperature and pressure unit to cooperate with each other, perform information exchange to form a closed-loop control, and complete the coordinated action control of the degree of drug atomization, drug temperature, drug injection volume, abdominal gas temperature, abdominal gas pressure, and exhaust purification, thereby realizing high-pressure atomization heating drug delivery treatment in the abdominal cavity; The high-voltage generating unit includes an explosion-proof syringe, a liquid pipe, and an atomizing nozzle, wherein the liquid pipe is a high-pressure resistant pipe; the explosion-proof syringe is loaded with a liquid for drug administration, and the two ends of the liquid pipe are respectively connected to the liquid outlet of the explosion-proof syringe and the liquid inlet of the atomizing nozzle; the atomizing end is provided on the atomizing nozzle; the piston is provided in the explosion-proof syringe, one end of the piston is in contact with the liquid medicine, and the other end is connected to the movable end of the transmission unit; The particle size of the mist liquid sprayed by the atomizing nozzle is less than or equal to 10 μm, and the ultra-high pressure is 5-9 MPa; The explosion-proof syringe comprises a barrel, an explosion-proof shell, and the piston; the explosion-proof shell is sleeved over the barrel, one end of the explosion-proof shell is sealedly connected to the outer wall of the liquid outlet end of the barrel, and is provided with a hole for the liquid outlet end to extend out; the other end of the explosion-proof shell is provided with an openable and closable sealing component; the sealing component is used to replace the barrel when opened, and to allow the movable end of the transmission unit to pass through and seal the outer wall of the movable end when closed; The transmission unit includes a transmission screw and a transmission nut. The output end of the power unit is in transmission connection with the transmission screw or the transmission nut. The power unit transmits the output rotation to the transmission screw or the transmission nut. The transmission screw or the transmission nut converts the rotation into displacement and transmits it to the piston. The power unit includes a servo motor and a servo driver. The output end of the servo motor is connected to the input end of the transmission unit, and the transmission unit receives the rotation of the servo motor; the servo driver is electrically connected to the servo motor, and the servo driver is electrically connected to the central control module to receive data from the central control module for controlling the start displacement, stop displacement, and displacement distance and speed of the piston; The negative pressure unit includes a suction component, a filter component, and a suction tube; the suction tube is used to extend into the abdominal cavity and suck out the abdominal aerosol by the negative pressure suction force generated by the suction component, and the sucked abdominal aerosol is filtered and purified by the filter component before being discharged; The suction component is connected to the air outlet end of the filter component through a pipeline, and the suction tube is connected to the air inlet end of the filter component; the filter component is filled with a purification liquid, and the peritoneal aerosol sucked by the suction tube is passed into the purification liquid. After the purification liquid absorbs the pollutants in the peritoneal aerosol, the purified gas is released. The purified gas enters the suction component through the air outlet end of the filter component and is discharged through the suction component; Alternatively, the suction tube is connected to the negative pressure end of the suction component, and the exhaust end of the suction component is connected to the filter component via a pipe, and the suction component passes the sucked abdominal aerosol into the air inlet end of the filter component; the filter component is filled with a purification liquid, and the abdominal aerosol passes into the purification liquid, and the purified liquid releases purified gas after absorbing the pollutants in the abdominal aerosol, and the purified gas is discharged through the air outlet end of the filter component; A liquid quality sensor is provided in the purified liquid of the filter component, and the liquid quality sensor is electrically connected to the central control module, and is used to monitor the contamination degree of the purified liquid and output the contamination data of the purified liquid to the central control module. The central control module determines the contamination degree or cleanliness of the purified liquid through a built-in algorithm; A gas quality sensor is provided inside or outside the gas outlet of the filter component, on the path of the discharged purified gas, for monitoring the contamination level of the purified gas and outputting the contamination data of the purified gas to the central control module, which determines the contamination level or cleanliness of the purified gas through a built-in algorithm; The temperature and pressure unit includes a liquid medicine heater, a first temperature sensor, and a second temperature sensor electrically connected to the central control module; the liquid medicine heater is provided on the high-voltage generating unit and heats the liquid medicine loaded in the high-voltage generating unit to a preset temperature of the central control module; the first temperature sensor is used to monitor the real-time temperature of the liquid medicine, and the second temperature sensor is used to monitor the output temperature of the liquid medicine heater, and transmits the real-time temperature of the liquid medicine and the output temperature data of the liquid medicine heater to the central control module, and the central control module performs closed-loop control on the real-time temperature of the liquid medicine and the liquid medicine heater; and an abdominal cavity heater, a third temperature sensor, and a fourth temperature sensor electrically connected to the central control module; the abdominal cavity heater is arranged on the abdomen, and is used to heat the abdomen and transfer heat to the abdominal cavity gas in the abdominal cavity, so that the abdominal cavity gas is heated to a preset temperature of the central control module; the third temperature sensor is used to monitor the real-time temperature of the abdominal cavity gas, and the fourth temperature sensor is used to monitor the output temperature of the abdominal cavity heater, and transmit the real-time temperature of the abdominal cavity gas and the output temperature data of the abdominal cavity heater to the central control module, and the central control module performs closed-loop control on the real-time temperature of the abdominal cavity gas and the abdominal cavity heater; and an abdominal pressure sensor electrically connected to the central control module, the abdominal pressure sensor being used to monitor the abdominal pressure and transmit the abdominal pressure data to the central control module. The central control module, in conjunction with the power unit, controls the pressure and flow of the atomized liquid sprayed by the high-pressure generating unit, and controls the pressure and flow of the abdominal aerosol sucked out by the negative pressure unit, thereby collaboratively controlling the abdominal pressure in a closed-loop control manner; The high-voltage generating unit is equipped with a limit module, a position detection module and a liquid medicine pressure module which are electrically connected to the central control module and exchange data with each other; the limit module is used to obtain the starting position and final position of the piston and feed back the starting position and final position data of the piston to the central control module; the position detection module is used to obtain the current position of the piston and feed back the current position data of the piston to the central control module, and the current liquid medicine injection volume is calculated by the built-in algorithm of the central control module; The medicine liquid pressure module is used to detect the current pressure of the medicine liquid in the high-voltage generating unit and feed back the current pressure data of the medicine liquid to the central control module.

2. The peritoneal atomization drug delivery device according to claim 1, characterized in that: The barrel of the explosion-proof syringe is a thickened disposable barrel.

3. The peritoneal atomization drug delivery device according to claim 2, characterized in that: The barrel of the explosion-proof syringe is made of high-pressure-resistant and corrosion-resistant materials.

4. The peritoneal atomization drug delivery device according to claim 1, characterized in that: When the transmission screw receives the rotation of the power unit, the transmission nut moves in a straight line along the axis of the transmission screw, and the transmission nut transmits the displacement to the piston; The transmission unit is further provided with a guide rod, which is slidably connected to the transmission nut; A push rod is further provided between the transmission nut and the piston. The push rod connects the transmission nut and the piston, and the piston and the push rod are detachable.

5. The peritoneal atomization drug delivery device according to claim 1, characterized in that: When the transmission nut receives the rotation of the power unit, the transmission screw moves in a straight line along the axis of the transmission nut, and the transmission screw transmits the displacement to the piston; The transmission unit is provided with a rotating base, the transmission nut is rotatably mounted on the rotating base, and the power unit is rotatably connected to the transmission nut to drive the transmission nut to rotate; The transmission screw rod passes through the central screw hole of the transmission nut, and the transmission nut drives the transmission screw rod to move.

6. The peritoneal atomization drug delivery device according to claim 1, characterized in that: The power unit is equipped with a rotation sensor for detecting the number of rotations and the rotation speed output by the power unit, and feeding back the number of rotations and the rotation speed data output by the power unit to the central control module.

7. The peritoneal atomization drug delivery device according to claim 6, characterized in that: The central control module obtains the starting position, final position and current position of the piston, obtains the current pressure data of the liquid medicine in the high-voltage generating unit, and obtains the number of rotations and rotation speed data output by the power unit, and coordinates the power unit, the transmission unit and the high-voltage generating unit in a closed-loop control manner to control the atomization degree and injection volume of the liquid medicine.

8. A sterile protective operating cover, characterized in that: The invention comprises a sterile operating sleeve and the abdominal atomization drug delivery device according to any one of claims 1 to 7, wherein the sterile protective operating sleeve is provided on the abdominal wound to isolate the abdominal wound from the external environment, and a sterile environment is formed inside the sterile operating sleeve, so that the atomization end can be extended into the abdominal cavity to be treated in a sterile manner to perform high-pressure atomization heating drug delivery treatment.

9. A PC processor, characterized in that: It comprises a PC processing unit and the peritoneal nebulizer drug delivery device according to any one of claims 1 to 7, wherein the PC processing unit is electrically connected to the central control module and performs data interaction, and is used to receive the drug delivery data set by the user and convert it into interactive data and transmit it to the central control module.

10. An interactor, characterized in that: It comprises an operation screen and a PC processor as claimed in claim 9, wherein the operation screen is electrically connected to the PC processing unit and performs data interaction, and is used for the user to set medication instructions, and convert them into interactive instructions and transmit them to the PC processing unit.

Images